Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy

被引:17
作者
Sakaida, Isao [1 ]
Okita, Kiwamu [2 ]
机构
[1] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi 7558505, Japan
[2] Shimonoseki Kosei Hosp, Social Insurance Alliance, Shimonoseki, Yamaguchi, Japan
关键词
abdominal circumference; ascites volume; bodyweight; correlation analysis; regression equation; tolvaptan; V-2 RECEPTOR ANTAGONIST; REFRACTORY ASCITES; CLINICAL-TRIAL; HEART-FAILURE; DOUBLE-BLIND; VASOPRESSIN; HYPONATREMIA; MANAGEMENT; SATAVAPTAN; EFFICACY;
D O I
10.1111/hepr.12171
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: Although it is an important treatment challenge to treat ascites with diuretic therapy, no objective markers have been established to assess improvement of ascites. However, change in bodyweight has been used as a marker of change in ascites volume. Thus, we evaluated the relationship between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with ascites. Methods: We calculated ascites volume in patients using the simple 5-point method by conventional computed tomography and conducted a correlation analysis between changes in bodyweight and changes in ascites volume as a part of our double-blind phase 3 trial of tolvaptan. Result: Change in bodyweight (x-axis) was correlated with change in ascites volume (y-axis) in all included patients (r = 0.52). A strong correlation were observed between the changes in patients without lower limb edema (r = 0.61). These correlations between the changes were expressed by the following linear regression equations: y = -0.102 + 0.206x or y = -0.033 + 0.292x, respectively. Proportions of change in ascites volume to change in bodyweight were estimated to be nearly 30%. Therefore, bodyweight reduction was confirmed to lead to improvement in ascites. Conclusion: Change in bodyweight can be an objective marker to assess improvement of hepatic edema in the short-term diuretic therapy in everyday clinical practice. Decrease in ascites volume was estimated to account for nearly 30% of bodyweight reduction.
引用
收藏
页码:735 / 739
页数:5
相关论文
共 26 条
  • [1] Therapeutic potential of vasopressin receptor antagonists
    Ali, Farhan
    Guglin, Maya
    Vaitkevicius, Peter
    Ghali, Jalal K.
    [J]. DRUGS, 2007, 67 (06) : 847 - 858
  • [2] Unilateral leg edema in a cirrhotic patient with tense ascites
    Assimakopoulos, Stelios F.
    Thomopoulos, Konstantinos C.
    Kalogeropoulou, Christine
    Maroulis, Ioannis
    Lekkou, Alexandra
    Papakonstantinou, Christos
    Vagianos, Constantine E.
    Gogos, Charalambos
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (35) : 5746 - 5747
  • [3] Abdominal bloating
    Azpiroz, F
    Malagelada, JR
    [J]. GASTROENTEROLOGY, 2005, 129 (03) : 1060 - 1078
  • [4] Non-peptide arginine-vasopressin antagonists: the vaptans
    Decaux, Guy
    Soupart, Alain
    Vassart, Gilbert
    [J]. LANCET, 2008, 371 (9624) : 1624 - 1632
  • [5] Spot urinary sodium for assessing dietary sodium restriction in cirrhotic ascites
    El-Bokl, Mohammed Abdelhamid
    Senousy, Bahaa Eldeen
    El-Karmouty, Khaled Zakaria
    Mohammed, Inas El-Khedr
    Mohammed, Sherif Monier
    Shabana, Sherif Sadek
    Shalaby, Hassan
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (29) : 3631 - 3635
  • [6] Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)
    Gassanov, Natig
    Semmo, Nasser
    Semmo, Mariam
    Nia, Amir M.
    Fuhr, Uwe
    Er, Fikret
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (04) : 333 - 346
  • [7] The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study
    Ghali, Jalal K.
    Orlandi, Cesare
    Abraham, William T.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2012, 14 (06) : 642 - 651
  • [8] Current concepts -: Management of cirrhosis and ascites
    Ginès, P
    Cárdenas, A
    Arroyo, V
    Rodes, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (16) : 1646 - 1654
  • [9] Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia - a randomized, double-blind, placebo-controlled study
    Gines, P.
    Wong, F.
    Watson, H.
    Terg, R.
    Bruha, R.
    Zarski, J. -P.
    Dudley, F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (08) : 834 - 845
  • [10] Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia:: A randomized trial
    Gines, Pere
    Wong, Florence
    Watson, Hugh
    Milutinovic, Slobodan
    del Arbol, Luis Ruiz
    Olteanu, Dan
    [J]. HEPATOLOGY, 2008, 48 (01) : 204 - 213